Department of Haematology, University College London, London, UK.
Nuffield Department of Population Health, National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK.
Intern Med J. 2020 Dec;50(12):1538-1546. doi: 10.1111/imj.14942.
Gaucher disease (GD) manifests heterogeneously and other conditions are often misdiagnosed in its place, leading to diagnostic delays. The Gaucher Earlier Diagnosis Consensus (GED-C) initiative proposed a point-scoring system (PSS) based on the signs and covariables that are most indicative of GD to help clinicians identify which individuals to test for GD.
To validate the PSS retrospectively in a test population including patients with GD and other conditions with overlapping manifestations.
Four cohorts of adults with GD, liver disease, haematological malignancy or immune thrombocytopenia were identified from hospital records. Clinical data were audited for GED-C factors identified as potentially indicative of GD and aggregate scores calculated (sum of scores/number of factors) based on published PSS weightings. Threshold discriminatory PSS scores, sensitivity and specificity were determined by receiver-operating characteristic analysis.
Among 100 patients (GD, n = 25; non-GD, n = 75), analyses based on 11 possible factors estimated group mean (standard deviation) PSS scores of: GD (n = 14), 1.08 (0.25); non-GD (n = 38), 0.58 (0.31). Mean between-group difference (95% confidence interval) was -0.49 (-0.68, -0.31) and area under the receiver-operating characteristic analysis curve (95% confidence interval) was 0.88 (0.78, 0.97). A threshold PSS score of 0.82 identified all 14 patients with GD in the analysis set (100% sensitivity) and 27 of 38 patients in the non-GD group (71% specificity). Patients with liver disease and haematological malignancy were most likely to have manifestations overlapping GD.
Preliminary validation of the GED-C PSS discriminated effectively between patients with GD and those with overlapping signs.
戈谢病(GD)表现异质性,其他疾病常误诊为该病,导致诊断延迟。戈谢病早期诊断共识(GED-C)倡议提出了一种基于最能提示 GD 的体征和协变量的评分系统(PSS),以帮助临床医生识别哪些个体需要进行 GD 检测。
在包括 GD 患者和其他表现重叠的疾病患者的测试人群中,对 PSS 进行回顾性验证。
从医院记录中确定了 4 组成年 GD 患者、肝病患者、血液恶性肿瘤患者和免疫性血小板减少症患者。对 GED-C 因素进行了临床数据审核,这些因素被认为可能提示 GD,并根据已发表的 PSS 权重计算了总评分(评分总和/因素数量)。通过接收者操作特征分析确定了有区分力的 PSS 评分阈值、敏感性和特异性。
在 100 名患者(GD 患者,n=25;非 GD 患者,n=75)中,基于 11 个可能因素的分析估计了组平均值(标准差)PSS 评分:GD(n=14),1.08(0.25);非 GD(n=38),0.58(0.31)。组间平均差异(95%置信区间)为-0.49(-0.68,-0.31),接收者操作特征分析曲线下面积(95%置信区间)为 0.88(0.78,0.97)。PSS 评分阈值为 0.82 时,可在分析集中识别出所有 14 名 GD 患者(敏感性 100%)和非 GD 组中 27 名患者(特异性 71%)。患有肝病和血液恶性肿瘤的患者最有可能出现与 GD 重叠的表现。
GED-C PSS 的初步验证可有效区分 GD 患者和表现重叠的患者。